سعر اروزول 100مجم 14 كبسولة 2022

Arozole 100 mg capsules (itraconazole 100 mg), a triazole systemic antifungal made by Alfacure Pharmaceuticals, Egypt; pack of 14 capsules (2 strips).

• Blastomycosis, pulmonary and extrapulmonaryPopulation: Immunocompromised and non-immunocompromised adults (US label)DailyMed (U.S. National Library of Medicine)
• Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosisPopulation: Immunocompromised and non-immunocompromised adults (US label)DailyMed (U.S. National Library of Medicine)
• Aspergillosis, pulmonary and extrapulmonary, in patients intolerant of or refractory to amphotericin BPopulation: Immunocompromised and non-immunocompromised adults (US label)DailyMed (U.S. National Library of Medicine)

• In systemic fungal infection trials the most frequent adverse reactions were nausea (11%), rash (9%), vomiting (5%), edema, headache, diarrhoea, fatigue, fever, pruritus, hypertension, hypokalemia and abnormal hepatic function.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Postmarketing: leukopenia, neutropenia, thrombocytopenia, anaphylaxis and serum sickness, peripheral neuropathy, visual disturbances, hearing loss, congestive heart failure, pulmonary edema, pancreatitis, serious hepatotoxicity, toxic epidermal necrolysis, Stevens-Johnson syndrome, AGEP, alopecia, photosensitivity, urinary incontinence and erectile dysfunction.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Coadministration with certain CYP3A4 substrates that can cause serious reactions (e.g. QT prolongation, torsades de pointes), including methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids, irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, isavuconazole, finerenone and voclosporin.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Colchicine, fesoterodine and solifenacin in patients with varying degrees of renal or hepatic impairment; venetoclax in CLL/SLL during initiation and ramp-up.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - congestive heart failure: itraconazole has negative inotropic effects; if signs or symptoms of CHF occur, reassess and consider discontinuation. Do not use for onychomycosis in ventricular dysfunction.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning - drug interactions: coadministration with certain CYP3A4 substrates can raise their plasma levels and cause serious cardiovascular events including QT prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest and sudden death.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatotoxicity: rare cases of serious hepatotoxicity including liver failure and death, some in patients without pre-existing liver disease; stop treatment and check liver function if symptoms occur; consider liver function monitoring.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducers (rifampicin, rifabutin, isoniazid, phenobarbital, phenytoin, carbamazepine, efavirenz, nevirapine)These can markedly reduce itraconazole concentrations; use is not recommended from 2 weeks before and during itraconazole treatment (for rifabutin and carbamazepine also for 2 weeks after).DailyMed (U.S. National Library of Medicine)
• CYP3A4 inhibitors (clarithromycin, erythromycin, ciprofloxacin, ritonavir-boosted protease inhibitors, diltiazem)These may increase itraconazole concentrations; monitor for adverse effects and adjust dose if needed.DailyMed (U.S. National Library of Medicine)
• Gastric acid reducers (antacids, H2-receptor antagonists, proton pump inhibitors)Reduced gastric acidity decreases absorption of itraconazole capsules; give antacids at least 2 hours before or 2 hours after itraconazole.DailyMed (U.S. National Library of Medicine)

• Itraconazole caused dose-related maternal toxicity, embryotoxicity and teratogenicity in rats and mice; there are no studies in pregnant women. Use for systemic fungal infections in pregnancy only if the benefit outweighs the potential risk; do not use for onychomycosis in pregnancy. Congenital abnormalities have been reported postmarketing.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Women of childbearing potential treated for onychomycosis should use effective contraception, starting therapy on day 2 or 3 of menses, and continue highly effective contraception throughout therapy and for 2 months after the end of treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Itraconazole is excreted in human milk; weigh the expected benefits for the mother against the potential risk to the infant.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Itraconazole: Triazole antifungal that inhibits cytochrome P450-dependent synthesis of ergosterol, a vital component of fungal cell membranes (US label).